Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 101–200 of 1,000
Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies
Vinjamur, D. S., Bauer, D. E., & Orkin, S. H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15038 · Cited by 114
Micro-/nanoscale electroporation
Chang, L., Li, L., Shi, J., Sheng, Y., Lu, W., Gallego‐Perez, D., & Lee, L. J. (2016) · Lab on a Chip · doi:10.1039/c6lc00840b · Cited by 125
Cai, X., Jin, R., Wang, J., Yue, D., Jiang, Q., Wu, Y., & Gu, Z. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b11545 · Cited by 115
Gutiérrez-Guerrero, A., Cosset, F., & Verhoeyen, E. (2020) · Viruses · doi:10.3390/v12091016 · Cited by 131
“Gene therapy’s main challenge is to achieve a durable expression of the therapeutic gene in a large percentage of the target cells without changing their normal physiology [5,74].”
BackgroundFeng, J., Xu, Z., Liu, F., Zhao, Y., Yu, W., Pan, M., Wang, F., & Liu, X. (2018) · ACS Nano · doi:10.1021/acsnano.8b08101 · Cited by 113
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
Naldini, L. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809958 · Cited by 110
“…started with premature and overly hyped expectations, soon faced unexpected hurdles and toxicity derailing its course and only recently reached safe and successful clinical results in a growing number of diseases thanks to an improved generation of tools (Naldini, 2011, 2015; Dunbar et al, 2018).”
BackgroundSelf-citationAlmeida, A. M., Queiroz, J. A., de Sousa, F. P., & Sousa, Â. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.011 · Cited by 130
Sharpening the Molecular Scissors: Advances in Gene-Editing Technology
Broeders, M., Herrero-Hernandez, P., Ernst, M. P. T., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2019) · iScience · doi:10.1016/j.isci.2019.100789 · Cited by 130
“From agriculture to biomedical science, these platforms are being explored in various fields and, more recently, in the first clinical trials (Barrangou and Doudna, 2016; Naldini, 2015; Rodriguez-Rodriguez et al., 2019; Zhan et al., 2019).”
BackgroundGene therapy: a double-edged sword with great powers
Tang, R., & Xu, Z. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03834-3 · Cited by 135
Hydrogel armed with Bmp2 mRNA-enriched exosomes enhances bone regeneration
Yang, Z., Li, X., Gan, X., Wei, M., Wang, C., Yang, G., Zhao, Y., Zhu, Z., & Wang, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01871-w · Cited by 109
The Recent Advances of Magnetic Nanoparticles in Medicine
Guo, T., Lin, M., Huang, J., Zhou, C., Tian, W., Yu, H., Jiang, X., Ye, J., Shi, Y., Xiao, Y., et al. (2018) · Journal of Nanomaterials · doi:10.1155/2018/7805147 · Cited by 113
“Stably transferring exogenous gene into target cell for gene therapy depends on the gene transfer system [40], and stable and effective gene vector is of importance to gene therapy [41].”
BackgroundAn RGD-modified hollow silica@Au core/shell nanoplatform for tumor combination therapy
Li, X., Xing, L., Hu, Y. M., Xiong, Z., Wang, R., Xu, X., Du, L., Shen, M., & Shi, X. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.08.024 · Cited by 108
“Introduction Various cancer therapy methods have been adopted to kill cancer [1-3].”
BackgroundDrug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
“Gene transfer efficacy is typically limited by insufficient delivery to the target tissue, negative immune response (autoantibody) to the treatment, and loss of therapeutic effect over time (Naldini, 2015; Sasano, Kikuchi, McDonald, Lai, & Donahue, 2007).”
BackgroundAntisense Oligonucleotide-Based Therapy for Neuromuscular Disease
Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., & Falzarano, M. S. (2017) · Molecules · doi:10.3390/molecules22040563 · Cited by 118
“Among these new compounds, antisense oligonucleotides (ASOs) have been recognized for the treatment of neurodegenerative disorders [3].”
BackgroundAdvancements and Obstacles of CRISPR-Cas9 Technology in Translational Research
You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lü, Y. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.008 · Cited by 128
Nucleic Acid–Based Functional Nanomaterials as Advanced Cancer Therapeutics
Yuan, Y., Gu, Z., Yao, C., Luo, D., & Yang, D. (2019) · Small · doi:10.1002/smll.201900172 · Cited by 113
Arora, S., Sharma, D., & Singh, J. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00076 · Cited by 107
Adipose Stem Cell Translational Applications: From Bench-to-Bedside
Argentati, C., Morena, F., Bazzucchi, M., Armentano, I., Emiliani, C., & Martino, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113475 · Cited by 115
Virus-like nanoparticles as a novel delivery tool in gene therapy
Jeevanandam, J., Pal, K., & Danquah, M. K. (2018) · Biochimie · doi:10.1016/j.biochi.2018.11.001 · Cited by 108
Jaiswal, S., Dutta, P. K., Kumar, S., Koh, J., & Pandey, S. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.01.104 · Cited by 105
Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases
Poletti, V., & Mavilio, F. (2021) · Viruses · doi:10.3390/v13081526 · Cited by 121
“These studies were the basis for the development of a safer and more efficacious vectors, derived from the human immunodeficiency lentivirus (HIV) and carrying carefully designed transgene expression cassettes based on cellular promoters and regulatory elements [6].”
BackgroundLiu, H., Zhang, H., Han, Y., Hu, Y., Geng, Z., & Su, J. (2022) · Theranostics · doi:10.7150/thno.78034 · Cited by 106
Kruta, M., Sunshine, M. J., Chua, B. A., Fu, Y., Chawla, A., Dillingham, C. H., Hidalgo San Jose, L., De Jong, B., Zhou, F. J., & Signer, R. A. J. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.07.009 · Cited by 100
Zhao, H., Zhang, Z., Zuo, D., Li, L., Li, F., & Yang, D. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01727 · Cited by 103
Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells
Nakahara, F., Borger, D. K., Wei, Q., Pinho, S., Maryanovich, M., Zahalka, A. H., Suzuki, M., Cruz, C. D., Wang, Z., Xu, C., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0308-3 · Cited by 99
Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease
Ernst, M. P. T., Broeders, M., Herrero-Hernandez, P., Oussoren, E., van der Ploeg, A. T., & Pijnappel, W. W. M. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.022 · Cited by 108
“By optimizing the lentiviral backbone and by controlling the number of viral copies, it has been demonstrated inmultiple clinical trials that lentiviral gene therapy is safe provided that it is used with the proper precautions.(2,4) AAV-mediated gene therapy does not rely on integration into the host genome but instea…”
MethodRichter, M., Saydaminova, K., Yumul, R., Krishnan, R., Liu, J., Nagy, E.-E., Singh, M., Izsvák, Z., Cattaneo, R., Uckert, W., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711580 · Cited by 102
Host determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 97
Schmid, M., Ernst, P. J., Honegger, A., Suomalainen, M., Zimmermann, M., Braun, L., Stauffer, S., Thom, C., Dreier, B., Eibauer, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02707-6 · Cited by 98
Regulation and targeting of SREBP-1 in hepatocellular carcinoma
Su, F., & Koeberle, A. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10156-5 · Cited by 122
“…of SREBP-1 target genes, such as ACC, FASN, SCD1, and ACLY [32, 390–392]; (ii) interference with defined, context-specific SREBP-1 regulators, e.g., PKD3 or CRTC2 [128, 198, 204]; (iii) functionalized nanoparticles for HCC targeting [393–395]; and (iv) tumor-specific gene therapy [223, 396].”
BackgroundTargeting mutant KRAS with CRISPR-Cas9 controls tumor growth
Kim, W., Lee, S., Kim, H. S., Song, M., Cha, Y. H., Kim, Y.-H., Shin, J., Lee, E.-S., Joo, Y., Song, J. J., et al. (2018) · Genome Research · doi:10.1101/gr.223891.117 · Cited by 97
“deliver transgenes into cancer cells (Yin et al. 2014; Naldini 2015).”
BackgroundExosome-based small RNA delivery: Progress and prospects
Lu, M., Xing, H., Xun, Z., Yang, T., Ding, P., Cai, C., Wang, D., & Zhao, X. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.07.008 · Cited by 97
“Gene therapy, including RNAi, has long been fascinating both scientific community and general public because of the potential for treating a diseases at its genetic roots [1].”
BackgroundMicro and nanotechnologies for bone regeneration: Recent advances and emerging designs
Mohammadi, M., Shaegh, S. A. M., Alibolandi, M., Ebrahimzadeh, M. A., Tamayol, A., Jaafari, M. R., & Ramezani, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.032 · Cited by 106
“Thus, the efficiency and safety of gene vectors should be upgraded by further improvement of the transfection efficiency and bypassing the immunity system against the gene-vector complex [178].”
BackgroundMeng, Z., Luan, L., Kang, Z., Feng, S., Meng, Q., & Liu, K. (2017) · Journal of Materials Chemistry B · doi:10.1039/c6tb02862d · Cited by 101
TRIM11 protects against tauopathies and is down-regulated in Alzheimer’s disease
Zhang, Z.-Y., Harischandra, D. S., Wang, R., Ghaisas, S., Zhao, J. Y., McMonagle, T. P., Zhu, G., Lacuarta, K. D., Song, J., Trojanowski, J. Q., et al. (2023) · Science · doi:10.1126/science.add6696 · Cited by 95
“AAVs can transduce the nondividing neurons and permit permanent expression of the therapeutic gene after a single administration (73, 74), with positive clinical outcomes (75).”
BackgroundParums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.944204 · Cited by 109
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
Rare genetic diseases: update on diagnosis, treatment and online resources
Pogue, R. E., Cavalcanti, D. P., Shanker, S., de Andrade, R. V., Aguiar, L. R., Carvalho, J. L., & Costa, F. F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.002 · Cited by 116
Tajer, P., Pike-Overzet, K., Arias, S., Havenga, M., & Staal, F. J. T. (2019) · Cells · doi:10.3390/cells8020169 · Cited by 93
Algarni, A., Pilkington, E. H., Suys, E. J. A., Al-Wassiti, H. A., Pouton, C. W., & Truong, N. P. (2022) · Biomaterials Science · doi:10.1039/d2bm00168c · Cited by 99
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Self-citationDevelopments in anti-complement therapy; from disease to clinical trial
Harris, C. L., Pouw, R. B., Kavanagh, D., Sun, R., & Ricklin, D. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.008 · Cited by 91
Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy
Yu, J., Zhou, B., Zhang, S., Yin, H., Sun, L., Pu, Y., Zhou, B., Sun, Y., Li, X., Fang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35580-z · Cited by 104
Cancer Nanomedicine: A New Era of Successful Targeted Therapy
El-Readi, M. Z., & Althubiti, M. (2019) · Journal of Nanomaterials · doi:10.1155/2019/4927312 · Cited by 103
“Transferring genetic materials into host cells can be conducted using viral, bacterial vectors, or nonviral vectors such as liposome and nanoparticles [140].”
BackgroundResearch progress in membrane fusion-based hybrid exosomes for drug delivery systems
Liu, A., Yang, G., Liu, Y., & Liu, T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.939441 · Cited by 88
“Since most of the current reports on exosomes as drug carriers are related to small nucleic acids such as miRNA and siRNA or small-molecular-weight drugs, the expression plasmid of Cas9 is at least 5–6 kb (Naldini, 2015), which is much larger than the small nucleic acids.”
BackgroundUchida, S., & Kataoka, K. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36614 · Cited by 88
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
“, 2016), and promising results from numerous ongoing clinical trials may herald the emergence of other products in the near future (Naldini, 2015; Pierce and Bennett, 2015).”
BackgroundCombating deleterious phase transitions in neurodegenerative disease
Darling, A. L., & Shorter, J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.118984 · Cited by 85
Chen, W., Yao, S., Wan, J., Tian, Y., Huang, L., Wang, S., Akter, F., Wu, Y., Yao, Y., & Zhang, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.029 · Cited by 83
Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation
Lei, S., Zhang, X., Men, K., Gao, Y., Yang, X., Wu, S., Duan, X., Wei, Y., & Tong, R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00451 · Cited by 83
RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA
Aguiar, S. P., van der Gaag, B., & Cortese, F. A. B. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0101-9 · Cited by 92
Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
Wagner, T. E., Becraft, J. R., Bodner, K., Teague, B. P., Zhang, X., Woo, A. R. E., Porter, E. B., Alburquerque, B., Dobosh, B. S., Andries, O., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0146-9 · Cited by 85
Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82
Sun, W., Li, Z., Zhou, X., Yang, G., & Yuan, L. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1534898 · Cited by 87
“The ideal drug delivery system should be safe and efficient (Naldini, 2015).”
BackgroundAn Intelligent Nanomachine Guided by DNAzyme Logic System for Precise Chemodynamic Therapy
Wang, Z., Yang, J., Qin, G., Zhao, C., Ren, J., & Qu, X. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204291 · Cited by 84
Amphiphilic carbon dots as versatile vectors for nucleic acid and drug delivery
Wang, H., He, X., Luo, T., Zhang, J., Liu, Y., & Yu, X. (2017) · Nanoscale · doi:10.1039/c7nr01029j · Cited by 80
Chen, G., Ma, B., Wang, Y., & Gong, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b03496 · Cited by 81
Zhang, T., Huang, Y., Ma, X., Gong, N., Liu, X., Liu, L., Ye, X., Hu, B., Li, C., Tian, J.-H., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02553 · Cited by 80
Molecular Network of Colorectal Cancer and Current Therapeutic Options
Huang, Z., & Yang, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852927 · Cited by 97
“Gene therapy has shown remarkable efficacy in recent clinical studies (133).”
BackgroundSelf‐Assembled Nanomedicines for Anticancer and Antibacterial Applications
Zhou, L., Qiu, T. A., Lv, F., Liu, L., Ying, J., & Wang, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800670 · Cited by 80
Multicomponent Reactions-Based Modified/Functionalized Materials in the Biomedical Platforms
Javanbakht, S., & Shaabani, A. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00799 · Cited by 83
Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H. A., & Truong, N. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111068 · Cited by 84
“Gene therapy has received considerable interest since the 2006 Nobel prize in medicine [1].”
BackgroundLou, X., Hu, Y., Zhang, H., Liu, J., & Zhao, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01199-3 · Cited by 83
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 96
You, X., Gu, Z., Huang, J. C., Kang, Y., Chu, C., & Wu, J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.040 · Cited by 84
Genetically Encoded DNA Origami for Gene Therapy In Vivo
Wu, X., Yang, C., Wang, H., Lu, X., Shang, Y., Liu, Q. L., Fan, J., Liu, J., & Ding, B. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02756 · Cited by 81
Extracellular vesicles set the stage for brain plasticity and recovery by multimodal signalling
Hermann, D. M., Peruzzotti-Jametti, L., Giebel, B., & Pluchino, S. (2024) · Brain · doi:10.1093/brain/awad332 · Cited by 77
Enzyme-Responsive Charge-Reversal Polymer-Mediated Effective Gene Therapy for Intraperitoneal Tumors
Qiu, N., Gao, J., Liu, Q., Wang, J., & Shen, Y. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00440 · Cited by 79
rAAV-compatible MiniPromoters for restricted expression in the brain and eye
de Leeuw, C. N., Korecki, A. J., Berry, G. E., Hickmott, J. W., Lam, S. L., Lengyell, T. C., Bonaguro, R. J., Borretta, L. J., Chopra, V., Chou, A. Y., et al. (2016) · Molecular Brain · doi:10.1186/s13041-016-0232-4 · Cited by 76
Zhou, J., Wu, Y., Wang, C., Cheng, Q., Han, S., Wang, X., Zhang, J., Deng, L., Zhao, D., Du, L., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02915 · Cited by 76
Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.008 · Cited by 76
Transposons: Moving Forward from Preclinical Studies to Clinical Trials
Tipanee, J., VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.128 · Cited by 81
Tuwahatu, C. A., Yeung, C. C., Lam, Y. W., & Roy, V. A. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.023 · Cited by 79
Piras, F., Riba, M., Petrillo, C., Lazarevic, D., Cuccovillo, I., Bartolaccini, S., Stupka, E., Gentner, B., Cittaro, D., Naldini, L., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707922 · Cited by 75
“Nevertheless, multiple incubations with high vector doses and prolonged ex vivo culture are required to reach clinically relevant transduction levels, potentially impacting HSPC biological properties (Kajaste-Rudnitski & Naldini, 2015).”
InfluentialSelf-citationSpadaccio, C., Antoniades, C. A., Nenna, A., Chung, C., Will, R., Chello, M., & Gaudino, M. F. L. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz214 · Cited by 78
Advances in cancer stem cell targeting: How to strike the evil at its root
Pützer, B. M., Solanki, M., & Herchenröder, O. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.013 · Cited by 77
Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes
dos Santos Rodrigues, B., Arora, S., Kanekiyo, T., & Singh, J. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146738 · Cited by 73
Liposome-integrated hydrogel hybrids: Promising platforms for cancer therapy and tissue regeneration
Sanati, M., & Yavari, S. A. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.008 · Cited by 82
Zeng, M., Zhou, D., Alshehri, F., Lara‐Sáez, I., Lyu, Y., Creagh-Flynn, J., Xu, Q., Sigen, A., Zhang, J., & Wang, W. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b04098 · Cited by 73
Milani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“Gene therapy has recently shown remarkable progress in clinical trials and promises to provide effective treatment for several genetic and acquired diseases (Naldini, 2015).”
BackgroundSelf-citationHeffner, G. C., Bonner, M., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 72
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Barca, C., Griessinger, C. M., Faust, A., Depke, D. A., Essler, M., Windhorst, A. D., Devoogdt, N., Brindle, K. M., Schäfers, M. A., Zinnhardt, B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph15010013 · Cited by 85
“Thousands of clinical trials utilizing gene therapy have been designed in the past 15 years to treat inherited disorders and a wide variety of acquired diseases [78,79], with a large majority applied to cancer therapy.”
BackgroundMethodHan, H., Xing, J., Chen, W., Jia, J., & Li, Q. (2023) · Nature Communications · doi:10.1038/s41467-023-36625-7 · Cited by 82
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 88
In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells
Feldmann, D. P., Cheng, Y., Kandil, R., Xie, Y., Mohammadi, M., Harz, H., SHARMA, A. K., Peeler, D. J., Moszczyńska, A., Leonhardt, H., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.017 · Cited by 79
Delivering living medicines with biomaterials
Harimoto, T., Jung, W., & Mooney, D. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-024-00766-y · Cited by 89
Fernández‐Ruiz, M., Meije, Y., Manuel, O., Akan, H., Carratalà, J., Aguado, J. M., & Delaloye, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.029 · Cited by 78
Different Methods of Delivering CRISPR/Cas9 Into Cells
Chandrasekaran, A. P., Song, M., Kim, K.-S., & Ramakrishna, S. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2018.05.001 · Cited by 81
Polyester-based nanoparticles for nucleic acid delivery
Zhao, J., Weng, G., Li, J., Zhu, J., & Zhao, J. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2018.07.027 · Cited by 70
Whittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69
“There have been many successes for gene therapy in the last decade [101–107], and the first gene therapy was licensed for human use in Europe in 2012 (Glybera) [108].”
BackgroundTian, Y., Zhou, M., Shi, H., Gao, S., Xie, G., Zhu, M., Wu, M., Chen, J., & Niu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01805 · Cited by 76
Preclinical evaluation of mesenchymal stem cells overexpressing VEGF to treat critical limb ischemia
Beegle, J. R., Magner, N. L., Kalomoiris, S., Harding, A., Zhou, P., Nacey, C., White, J. L., Pepper, K. A., Gruenloh, W., Annett, G., et al. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.53 · Cited by 74
Receptor-Based Artificial Metalloenzymes on Living Human Cells
Ghattas, W., Dubosclard, V., Wick, A., Bendelac, A., Guillot, R., Ricoux, R., & Mahy, J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04326 · Cited by 75
Morelli, K. H., Griffin, L. B., Pyne, N. K., Wallace, L. M., Fowler, A. M., Oprescu, S. N., Takase, R., Wei, N., Meyer‐Schuman, R., Mellacheruvu, D., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130600 · Cited by 74
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy
Robinson-Hamm, J. N., & Gersbach, C. A. (2016) · Human Genetics · doi:10.1007/s00439-016-1725-z · Cited by 83
“The positive results for both safety and efficacy in many ongoing clinical trials with AAV vectors for diverse conditions, and an approved product in Europe based on intramuscular injection of AAV (Glybera), also support this approach (Naldini 2015).”
BackgroundSO2 Donors and Prodrugs, and Their Possible Applications: A Review
Wang, W., & Wang, B. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00559 · Cited by 71
“Nevertheless, the same kind of studies at the tissue, organ, or animal level would require much more complicated work (Naldini, 2015).”
BackgroundBairagi, R. D., Reon, R. R., Hasan, M. M., Sarker, S. K., Debnath, D., Rahman, M. T., Rahman, S., Islam, M. A., Siddique, M. A. T., Bokshi, B., et al. (2025) · Discover Nano · doi:10.1186/s11671-025-04234-6 · Cited by 94
“The unique properties of polymeric nanoparticles, including their ability to encapsulate a wide range of therapeutic agents, controlled and sustained drug release, and improved drug stability, make them highly suitable for treating various ocular diseases [9].”
Arora, S., Kanekiyo, T., & Singh, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.203 · Cited by 67
PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness
Lechanteur, A., Furst, T., Évrard, B., Delvenne, P., Hubert, P., & Piel, G. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.058 · Cited by 79
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.